MNZO Stock Overview
Manzo Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and testing of patented and non-patented solutions and remedies.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Manzo Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.000001 |
52 Week High | US$0.000001 |
52 Week Low | US$0.000001 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -99.80% |
5 Year Change | -90.00% |
Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
MNZO | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | 0.08% | 1.2% |
1Y | n/a | 13.2% | 24.9% |
Return vs Industry: Insufficient data to determine how MNZO performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MNZO performed against the US Market.
Price Volatility
MNZO volatility | |
---|---|
MNZO Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.8% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MNZO has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MNZO's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1980 | n/a | Kenneth Manzo | www.lactofreedom.com |
Manzo Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and testing of patented and non-patented solutions and remedies. The company is involved in developing Lacto-Freedom, a patented probiotic, which aids in the digestion of lactose containing foods primarily for people with lactose intolerance; and a natural remedy for colic in babies. It was formerly known as Fortune Oil & Gas, Inc. and changed its name to Manzo Pharmaceuticals, Inc. in September 2014.
Manzo Pharmaceuticals, Inc. Fundamentals Summary
MNZO fundamental statistics | |
---|---|
Market cap | US$1.10k |
Earnings (TTM) | US$7.75m |
Revenue (TTM) | n/a |
0.0x
P/E Ratio0.0x
P/S RatioIs MNZO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MNZO income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$517.23k |
Gross Profit | -US$517.23k |
Other Expenses | -US$8.27m |
Earnings | US$7.75m |
Last Reported Earnings
Sep 30, 2005
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did MNZO perform over the long term?
See historical performance and comparison